Sierra Summit Advisors LLC Acquires Shares of 59,371 Theravance Biopharma, Inc. $TBPH

Sierra Summit Advisors LLC acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 59,371 shares of the biopharmaceutical company’s stock, valued at approximately $1,111,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Quarry LP purchased a new stake in shares of Theravance Biopharma during the third quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analyst Ratings Changes

TBPH has been the subject of a number of research reports. HC Wainwright boosted their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. BTIG Research reissued a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Weiss Ratings cut shares of Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 8th. Finally, B. Riley Financial boosted their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.83.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 7.65% of the company’s stock.

Theravance Biopharma Trading Up 1.8%

TBPH opened at $16.55 on Thursday. The firm has a market capitalization of $853.15 million, a PE ratio of 7.52 and a beta of 0.19. Theravance Biopharma, Inc. has a twelve month low of $9.10 and a twelve month high of $21.03. The firm’s 50-day moving average price is $15.90 and its 200 day moving average price is $17.52.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, analysts predict that Theravance Biopharma, Inc. will post 0.95 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.